


IDS Form PTO/SB/08: Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/571,241	
			Filing Date	September 3, 2004	
			First Named Inventor	Rajendra Kumar Joshi	
			Art Unit	1612	
			Examiner Name	Nannette Holloman	
			Attorney Docket Number	08201.0065-00000	
Sheet	1	of	2		



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. ¹	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		2002-0055063 A1	05-09-2002	Kumon et al.	
		2003-0013761 A1	01-16-2003	Joshi et al.	
		2004-0038889 A1	02-26-2004	Joshi et al.	
		2004-0054001 A1	03-18-2004	Joshi et al.	
		2005-0148664 A1	07-07-2005	Joshi et al.	
		4,959,389	09-25-1990	Speiser et al.	
		5,242,905	09-07-1993	Blank	
		5,648,386	07-15-1997	Resemann et al.	
		6,359,003 B1	03-19-2002	Joshi et al.	
		6,436,992 B1	08-20-2002	Joshi et al.	
		6,509,376 B1	01-21-2003	Joshi et al.	

Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		DE 25 30 372	01-13-1977	Dr. Walter Schweckendiek		Abstract
		DE 26 21 214	11-17-1977	Koronis GmbH		Abstract
		DE 40 14 525 A1	11-14-1991	Hohloch, Herbert		Abstract
		DE 100 00 577 A1	07-26-2001	Fumapharm AG		Abstract
		DE 101 01 307 A1	01-08-2002	Fumapharm AG		Abstract
		DE 102 17 314 A1	11-13-2003	Fumapharm AG		Abstract
		DE 197 21 099 A1	11-26-1998	Fumapharm AG		Abstract
		DE 198 39 566 A1	09-03-2000	Fumapharm AG		Abstract
		DE 198 53 487 A1	05-25-2000	Fumapharm AG		Abstract
		EP 0 312 697 B1	04-21-1993	Prof. Dr. Peter Paul Speiser and Dr. Rajendra K., Joshi		Abstract
		RU 2002 737 C1	11-15-1993	Boehringer Ingelheim (BOEH)		Abstract
		WO 98/27970	07-02-1998	National Research Council of Canada		
		WO 02/055063 A2	07-18-2002	Fumapharm AG		Abstract

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The PTO did not receive the following listed item(s) *

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.H./

IDS Form PTO/SB/08: Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/571,241	
			Filing Date	September 3, 2004	
			First Named Inventor	Rajendra Kumar Joshi	
			Art Unit	1612	
			Examiner Name	Nannette Holloman	
			Attorney Docket Number	08201.0065-00000	
Sheet	2	of	2		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials ⁷	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Translation ⁶
		BACHARACH-BUHLES M. et al., "Fumaric Acid Esters (FAEs) Suppress CD 15- and ODP 4-positive Cells in Psoriasis," Acta. Derm. Venereol. Suppl. (Stockh.), 1994, Suppl. 186:79-82		Abstract
		GUTZMER, R. et al., "Erfolgreiche Therapie Einer Haut- und Lungenkarzinome mit Fumarsäureestern," Hautarzt, Vol. 55, No. 6, 20 April 2004, pp. 553-557		

Examiner Signature	/Nannette Holloman/	Date Considered	03/13/2009
-----------------------	---------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.